Literature DB >> 23584879

Self administered screening for hereditary cancers in conjunction with mammography and ultrasound.

Charles H McDonnell1, David J Seidenwurm, Diana E McDonnell, Kristie A Bobolis.   

Abstract

We evaluated the feasibility of an automated tablet computer application providing a family and personal history based cancer risk assessment for hereditary breast, ovarian, endometrial and colorectal cancers. 1,002 women presenting for screening mammography and 1,000 presenting for ultrasound were offered screening. The application calculated the risk of BRCA mutations using BRCAPRO, Myriad and Tyrer-Cuzick risk assessment models. Lifetime risk of breast and ovarian cancer was assessed with the BRCAPRO, Claus and Tyrer-Cuzick models. Colorectal and endometrial cancer risk was calculated via the MMRpro model. Patients were identified as high-risk based on thresholds 10% or greater risk for carrying genetic mutations or 20% or greater lifetime risk of breast or ovarian cancer. The percent of women found to be high-risk by a single risk assessment tool ranged from 0.5 to 5.3%. Combining assessment tools found 9.3% of women to be high-risk. The risk assessments performed similarly for the mammography and ultrasound cohorts with yields (combining assessment tools) of 9.2 and 9.4% respectively. The average ages of all the high-risk women were 45.8 and 39.6 years for the mammography and ultrasound cohorts respectively. Difficulties encountered included a need for software upgrade, wireless network unreliability and hardware theft. Automated family history screening can identify women probably at high-risk for hereditary cancers efficiently. The number of women identified is increased by employing multiple risk assessment models simultaneously. Surveying women in conjunction with ultrasound identified women at increased risk as effectively and at a younger age than with screening mammography.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23584879     DOI: 10.1007/s10689-013-9641-z

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  30 in total

1.  Exemestane for breast-cancer prevention in postmenopausal women.

Authors:  Paul E Goss; James N Ingle; José E Alés-Martínez; Angela M Cheung; Rowan T Chlebowski; Jean Wactawski-Wende; Anne McTiernan; John Robbins; Karen C Johnson; Lisa W Martin; Eric Winquist; Gloria E Sarto; Judy E Garber; Carol J Fabian; Pascal Pujol; Elizabeth Maunsell; Patricia Farmer; Karen A Gelmon; Dongsheng Tu; Harriet Richardson
Journal:  N Engl J Med       Date:  2011-06-04       Impact factor: 91.245

2.  Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history.

Authors:  D A Berry; G Parmigiani; J Sanchez; J Schildkraut; E Winer
Journal:  J Natl Cancer Inst       Date:  1997-02-05       Impact factor: 13.506

3.  Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.

Authors:  Susan M Domchek; Tara M Friebel; Christian F Singer; D Gareth Evans; Henry T Lynch; Claudine Isaacs; Judy E Garber; Susan L Neuhausen; Ellen Matloff; Rosalind Eeles; Gabriella Pichert; Laura Van t'veer; Nadine Tung; Jeffrey N Weitzel; Fergus J Couch; Wendy S Rubinstein; Patricia A Ganz; Mary B Daly; Olufunmilayo I Olopade; Gail Tomlinson; Joellen Schildkraut; Joanne L Blum; Timothy R Rebbeck
Journal:  JAMA       Date:  2010-09-01       Impact factor: 56.272

4.  Prevalence of hereditary breast/ovarian carcinoma risk in patients with a personal history of breast or ovarian carcinoma in a mammography population.

Authors:  Francisco J Dominguez; Julie L Jones; Katherina Zabicki; Barbara L Smith; Michele A Gadd; Michele Specht; Daniel B Kopans; Richard H Moore; James S Michaelson; Kevin S Hughes
Journal:  Cancer       Date:  2005-11-01       Impact factor: 6.860

5.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.

Authors:  D Ford; D F Easton; M Stratton; S Narod; D Goldgar; P Devilee; D T Bishop; B Weber; G Lenoir; J Chang-Claude; H Sobol; M D Teare; J Struewing; A Arason; S Scherneck; J Peto; T R Rebbeck; P Tonin; S Neuhausen; R Barkardottir; J Eyfjord; H Lynch; B A Ponder; S A Gayther; M Zelada-Hedman
Journal:  Am J Hum Genet       Date:  1998-03       Impact factor: 11.025

Review 6.  Effectiveness of preventive interventions in BRCA1/2 gene mutation carriers: a systematic review.

Authors:  M J Bermejo-Pérez; S Márquez-Calderón; A Llanos-Méndez
Journal:  Int J Cancer       Date:  2007-07-15       Impact factor: 7.396

Review 7.  Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: a critical review of the literature.

Authors:  Ronit Calderon-Margalit; Ora Paltiel
Journal:  Int J Cancer       Date:  2004-11-10       Impact factor: 7.396

8.  Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.

Authors:  D F Easton; D Ford; D T Bishop
Journal:  Am J Hum Genet       Date:  1995-01       Impact factor: 11.025

9.  Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis.

Authors:  H F Vasen; J T Wijnen; F H Menko; J H Kleibeuker; B G Taal; G Griffioen; F M Nagengast; E H Meijers-Heijboer; L Bertario; L Varesco; M L Bisgaard; J Mohr; R Fodde; P M Khan
Journal:  Gastroenterology       Date:  1996-04       Impact factor: 22.682

10.  Familial ovarian screening--effective or ineffective?

Authors:  I J Jacobs; J Mackay; U Menon; S J Skates; A N Rosenthal; L Fraser
Journal:  Br J Cancer       Date:  2006-10-23       Impact factor: 7.640

View more
  3 in total

1.  Increasing referral of at-risk women for genetic counseling and BRCA testing using a screening tool in a community breast imaging center.

Authors:  Banu K Arun; Susan K Peterson; Lilian E Sweeney; Rachel D Bluebond; Rebecca S S Tidwell; Sukh Makhnoon; Anne C Kushwaha
Journal:  Cancer       Date:  2021-08-23       Impact factor: 6.860

2.  Tablet, web-based, or paper questionnaires for measuring anxiety in patients suspected of breast cancer: patients' preferences and quality of collected data.

Authors:  Maarten W Barentsz; Hester Wessels; Paul J van Diest; Ruud M Pijnappel; Cees Haaring; Carmen C van der Pol; Arjen J Witkamp; Maurice A van den Bosch; Helena M Verkooijen
Journal:  J Med Internet Res       Date:  2014-10-31       Impact factor: 5.428

3.  Use of Mobile Clinical Decision Support Software by Junior Doctors at a UK Teaching Hospital: Identification and Evaluation of Barriers to Engagement.

Authors:  Rakesh Patel; William Green; Muhammad Waseem Shahzad; Chris Larkin
Journal:  JMIR Mhealth Uhealth       Date:  2015-08-13       Impact factor: 4.773

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.